Kineta, Inc., founded in 2008 by Drs. Charles Magness and Shawn Iadonato, is a biotechnology company focused on the development of new, targeted immune modulating drugs. Our progressive business model is aimed at accelerating advancement of novel medicines to benefit patients and investors more quickly than traditional models.
Kineta’s corporate strategy is to discover novel compounds, advance them through early stage development then partner with larger biopharma companies to conduct late stage development and commercialization. With less than 50 employees we are developing five drug and vaccine programs focused on autoimmune diseases, antivirals and chronic pain. Our lead autoimmune drug, dalazatide (formerly ShK-186) is in the clinic and recently completed Phase I studies. Kineta’s drugs have unique mechanisms of action and are aimed at addressing unmet medical needs. We foster innovation through academic collaborations and grow by publishing ground-breaking science. Our corporate partners enable us to accelerate and complete preclinical drug development.
In March of 2014 Seattle Business Magazine named Kineta the winner in the field of biopharmaceutical achievement for its innovative approach to drug development and investor-friendly business plan.